EP3784241A4 - Tricyclic heterocycle compounds useful as hiv integrase inhibitors - Google Patents

Tricyclic heterocycle compounds useful as hiv integrase inhibitors Download PDF

Info

Publication number
EP3784241A4
EP3784241A4 EP19793407.8A EP19793407A EP3784241A4 EP 3784241 A4 EP3784241 A4 EP 3784241A4 EP 19793407 A EP19793407 A EP 19793407A EP 3784241 A4 EP3784241 A4 EP 3784241A4
Authority
EP
European Patent Office
Prior art keywords
compounds useful
hiv integrase
integrase inhibitors
tricyclic heterocycle
heterocycle compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19793407.8A
Other languages
German (de)
French (fr)
Other versions
EP3784241A1 (en
Inventor
Tao Yu
James M. Apgar
Alan Whitehead
Yonglian Zhang
Zhiyong Hu
Valerie W. SHURTLEFF
John A. Mccauley
Izzat T. Raheem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of EP3784241A1 publication Critical patent/EP3784241A1/en
Publication of EP3784241A4 publication Critical patent/EP3784241A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
EP19793407.8A 2018-04-27 2019-04-22 Tricyclic heterocycle compounds useful as hiv integrase inhibitors Withdrawn EP3784241A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862663377P 2018-04-27 2018-04-27
US201862664527P 2018-04-30 2018-04-30
PCT/US2019/028432 WO2019209667A1 (en) 2018-04-27 2019-04-22 Tricyclic heterocycle compounds useful as hiv integrase inhibitors

Publications (2)

Publication Number Publication Date
EP3784241A1 EP3784241A1 (en) 2021-03-03
EP3784241A4 true EP3784241A4 (en) 2022-01-19

Family

ID=68294232

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19793407.8A Withdrawn EP3784241A4 (en) 2018-04-27 2019-04-22 Tricyclic heterocycle compounds useful as hiv integrase inhibitors

Country Status (10)

Country Link
EP (1) EP3784241A4 (en)
JP (1) JP2021522254A (en)
KR (1) KR20210005139A (en)
CN (1) CN112088005A (en)
AU (1) AU2019260608A1 (en)
BR (1) BR112020021768A2 (en)
CA (1) CA3101180A1 (en)
MA (1) MA52367A (en)
MX (1) MX2020011317A (en)
WO (1) WO2019209667A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20201414A1 (en) 2018-05-31 2020-12-07 Shionogi & Co POLYCYCLICAL DERIVATIVE OF PIRIDONE
US11649236B2 (en) 2018-05-31 2023-05-16 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative
EP3801543A4 (en) 2018-06-05 2022-03-02 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
JP7441947B2 (en) * 2019-11-26 2024-03-01 ギリアード サイエンシーズ， インコーポレイテッド Processes and intermediates for preparing MCL1 inhibitors
CR20220418A (en) 2020-02-24 2022-10-10 Gilead Sciences Inc Tetracyclic compounds for treating hiv infection
HUE064467T2 (en) 2021-01-19 2024-03-28 Gilead Sciences Inc Substituted pyridotriazine compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183532A1 (en) * 2013-05-17 2014-11-20 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2017113288A1 (en) * 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463975A1 (en) * 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US7902182B2 (en) * 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183532A1 (en) * 2013-05-17 2014-11-20 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2017113288A1 (en) * 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019209667A1 *
ZUO XIAOFANG ET AL: "Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017)", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 28, no. 4, 3 April 2018 (2018-04-03), GB, pages 299 - 316, XP055870040, ISSN: 1354-3776, Retrieved from the Internet <URL:http://dx.doi.org/10.1080/13543776.2018.1438410> DOI: 10.1080/13543776.2018.1438410 *

Also Published As

Publication number Publication date
MA52367A (en) 2021-03-03
AU2019260608A1 (en) 2020-10-29
MX2020011317A (en) 2020-11-18
WO2019209667A1 (en) 2019-10-31
BR112020021768A2 (en) 2021-01-26
EP3784241A1 (en) 2021-03-03
CA3101180A1 (en) 2019-10-31
CN112088005A (en) 2020-12-15
JP2021522254A (en) 2021-08-30
KR20210005139A (en) 2021-01-13

Similar Documents

Publication Publication Date Title
EP3752144A4 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
EP3784241A4 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
EP3801543A4 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
EP3827009A4 (en) Heterobicyclic compounds for inhibiting the activity of shp2
IL266908A (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EP3229805A4 (en) Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
EP3548031A4 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
EP3464272A4 (en) Novel heterocyclic derivatives useful as shp2 inhibitors
EP3229804A4 (en) Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
EP3083641A4 (en) Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
EP3285582A4 (en) Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
TWI800498B (en) Bicyclic dihydropyrimidine-carboxamide derivatives as rho-kinase inhibitors
EP3402799A4 (en) Heterocyclic compounds as rsv inhibitors
EP3377065A4 (en) Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
EP3377066A4 (en) Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
EP3049081A4 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors
EP3389380A4 (en) Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
EP3008044A4 (en) Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP3978503A4 (en) ANNELATED 9-HYDROXY-1,8-DIOXO-1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-a]PYRAZINE-7-CARBOXAMIDES AS HIV INTEGRASE INHIBITORS
EP3303341A4 (en) Fused tricyclic heterocyclic compounds useful for treating hiv infection
EP3822276A4 (en) Heterocyclic compound as trk inhibitor
EP3774812A4 (en) Macrocyclic compounds as trk kinases inhibitors
EP3558305A4 (en) Heterocyclic compounds as hiv protease inhibitors
EP3573984A4 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors
EP4043450A4 (en) 2h-benzopyran derivatives as crac inhibitors

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAV Requested validation state of the european patent: fee paid

Extension state: MA

Effective date: 20201127

Extension state: MD

Effective date: 20201127

Extension state: TN

Effective date: 20201127

A4 Supplementary search report drawn up and despatched

Effective date: 20211216

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 487/16 20060101ALI20211210BHEP

Ipc: A61K 31/4985 20060101AFI20211210BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20230208